Deals, deals, deals everywhere and 2013 saw its fair share too; the pharmaceutical and biotech industry signed 3,122 between them which averaged out to 260 per month in a year that finished with a flurry of high valued deals.
• Over 3,120 deals signed in 2013, slightly down from 2012
• Top 10 deals had a combined value of $14.1billion
• 8 deals had a value exceeding $1billion
• The top ten dealmakers list was dominated by big pharma companies
The total number of deals for 2013 however was a slightly lower figure than 2012 which recorded 3,489 deals. Derived from Current Agreements, in this article we review the key trends of pharmaceutical dealmaking in 2013 touching on the top 10 deals of the year, leading dealmakers, therapy areas and industry sectors. There’s also full details of the top 50 life science partnering deals by deal value including company, headline value and deal terms.
The remaining part of this article is Premium content – see below for access options.
Purchase this article
$35.00 BUY NOW
For $35.00, purchase this 5,756-word article and receive immediate online access.
100% Satisfaction Guarantee.
Report: Merger and Acquisition Deals and Alliances of 2013
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity